1. Introduction: Dysport vs BOTOX

Dysport and BOTOX are botulinum toxin type A (BoNT-A) products used in aesthetic and therapeutic medicine. Although both temporarily inhibit acetylcholine release at cholinergic nerve terminals, they are distinct pharmaceutical preparations with different nonproprietary names, manufacturing processes, formulations and potency assays.

Dysport contains abobotulinumtoxinA and is manufactured by Ipsen. BOTOX contains onabotulinumtoxinA and is manufactured by Allergan, an AbbVie company. ［1,2］

Both products have been investigated in clinical trials for the temporary improvement of glabellar lines, among other indications. However, a comparison of Dysport and BOTOX requires particular attention to product-specific potency units, the numerical doses used in individual studies and the clinical endpoints being evaluated.

A dose ratio investigated in one trial should not be interpreted as a universal conversion formula.

This article examines the relevant distinctions and explains how to interpret comparative clinical evidence without extending study findings beyond their intended context.

2. Product Background: AbobotulinumtoxinA vs OnabotulinumtoxinA

Dysport and BOTOX belong to the same pharmacological class, but they are not the same pharmaceutical product.

Feature

Dysport

BOTOX

Nonproprietary name

AbobotulinumtoxinA

OnabotulinumtoxinA

Manufacturer

Ipsen

Allergan / AbbVie

Drug class

Botulinum toxin type A

Botulinum toxin type A

Potency units

Product-specific

Product-specific

Aesthetic evidence

Randomized trials in glabellar lines

Randomized trials in facial-line indications

Therapeutic evidence

Product-specific clinical programs

Product-specific clinical programs

The approved indications, dosing schedules, preparation instructions and safety information must be checked against the locally applicable prescribing information. ［1,2］

3. Why Dysport and BOTOX Units Are Not Directly Interchangeable

One of the most important considerations when comparing botulinum toxin products is that potency units are not a universal measurement shared across brands.

The potency of each preparation is established using a product-specific biological assay. Consequently, the number of units printed on a vial cannot be interpreted independently of the product to which those units belong.

BOTOX labeling explicitly states that its potency units are specific to its preparation and assay method and are not comparable to, or convertible into, units of other botulinum toxin products. Dysport also has product-specific dosing requirements. ［1,2］

3.1 What Does a Dose Ratio Mean?

A dose ratio describes the numerical relationship between the doses of two products used in a particular study.

For example, if investigators compare one product at a specified dose with another product at a different numerical dose, that ratio describes the trial protocol.

It does not automatically establish the same relationship for another treatment area, clinical indication or patient population.

Information

Appropriate Interpretation

A study uses different numerical doses

The investigators selected those doses for the trial

A study meets its non-inferiority criterion

The conclusion applies to the prespecified endpoint and margin

A study reports a difference in onset

The finding depends on the definition and measurement of onset

A study reports a difference in duration

The finding depends on the duration endpoint and follow-up

A dose ratio is reported

It is not automatically a universal conversion rule

A clinical study can support a specific comparison without establishing general interchangeability between Dysport and BOTOX.

4. What Direct Comparative Clinical Evidence Exists?

Randomized clinical studies have evaluated abobotulinumtoxinA and onabotulinumtoxinA in glabellar lines.

A Phase III study involving Chinese patients included abobotulinumtoxinA and an active onabotulinumtoxinA comparator. The trial assessed non-inferiority using a prespecified design. ［3］

The clinical conclusion must be interpreted in relation to the investigated population, doses, endpoint and statistical margin.

4.1 Understanding Non-Inferiority

A non-inferiority study evaluates whether an investigated treatment is not worse than its comparator by more than a predefined, clinically acceptable margin.

This differs from a superiority study, which is designed to establish whether one treatment produces a statistically superior result for the specified endpoint.

A successful non-inferiority analysis therefore does not establish superiority.

4.2 Why the Study Population Matters

Clinical findings may be influenced by participant characteristics, including baseline severity, previous treatment history and the indication being investigated.

Results obtained in a defined study population should not automatically be presented as directly representative of every patient group.

The same principle applies when interpreting clinical trials conducted in different geographic regions.

5. What Do Onset and Duration Studies Add?

Onset and duration are clinically relevant outcomes when evaluating botulinum toxin treatment.

Randomized studies have compared these outcomes among incobotulinumtoxinA, onabotulinumtoxinA and abobotulinumtoxinA using specified treatment regimens. ［4］

However, onset and duration are not always defined in the same way across studies.

5.1 Onset of Effect

Onset refers to the time at which a treatment effect becomes detectable according to a defined assessment method.

A study may use investigator assessment, patient-reported observations or a specific change in wrinkle severity.

These methods can produce different measurements of onset.

5.2 Duration of Effect

Duration refers to how long a defined treatment response persists.

A trial may assess duration through the time until loss of a predefined response, a change in severity score or another prespecified measure.

Consequently, a reported duration should always be interpreted together with the study's endpoint definition and follow-up schedule.

Table 3. Factors Affecting the Interpretation of Onset and Duration

Factor

Why It Matters

Product and dose

The trial evaluates a specific treatment regimen

Clinical indication

Outcomes may differ across treatment areas

Definition of onset

Determines when a response is considered detectable

Definition of duration

Determines when a response is considered to have ended

Assessment schedule

Influences when changes can be recorded

Statistical analysis

Determines how comparative findings are evaluated

A result observed in glabellar-line treatment should not automatically be extended to cervical dystonia, spasticity or other aesthetic regions.

6. Why Indication Matters in Dysport vs BOTOX Comparisons

Dysport and BOTOX have been studied in both aesthetic and therapeutic settings.

However, the clinical objective, administered dose, target muscles and outcome measures can differ substantially between indications.

For example, a glabellar-line study may assess improvement in wrinkle severity, while a spasticity study may evaluate muscle tone or functional outcomes.

A numerical dose ratio or clinical response observed in one indication therefore cannot automatically be transferred to another.

Indication

Examples of Relevant Outcomes

Glabellar lines

Wrinkle severity and responder rates

Cervical dystonia

Abnormal head position, pain and disability measures

Spasticity

Muscle tone and functional outcomes

Other aesthetic regions

Region-specific appearance and response measures

Comparative evidence should be interpreted within the indication investigated.

7. What About Safety?

Dysport and BOTOX have product-specific contraindications, warnings and adverse-event information. ［1,2］

Clinical trials may report adverse events observed under their protocols, but the interpretation of comparative safety depends on the number of participants, follow-up duration and the events being measured.

A study designed primarily to evaluate efficacy may not have sufficient statistical power to detect differences in uncommon adverse events.

Similarly, non-inferiority for an efficacy endpoint does not establish equivalent safety across all patient populations.

Before treatment, clinicians should consult the current locally approved prescribing information and assess patient-specific contraindications and precautions.

8. How Does Neuronox Fit Into the Comparative Evidence?

Neuronox is another botulinum toxin type A product, manufactured by Medytox Inc. in the Republic of Korea.

It has a separate product-specific clinical evidence program, including randomized comparisons with onabotulinumtoxinA.

A Phase III study published by Lee WS and colleagues investigated Neuronox and onabotulinumtoxinA in 314 participants with glabellar lines. The reported Week-4 responder rates were 93.7% and 94.5%, respectively, and the study met its prespecified non-inferiority criterion. ［5］

Additional published studies have evaluated Neuronox or Meditoxin, as named in the respective publications, in selected therapeutic indications. ［6–8］

These include essential blepharospasm, spastic equinus in children with cerebral palsy and post-stroke upper-limb spasticity.

The Neuronox evidence program provides product-specific information across aesthetic and therapeutic settings. Its findings should be interpreted according to the investigated indication, population, dose and endpoint.

9. How Should Dysport, BOTOX and Neuronox Evidence Be Compared?

An evidence-based comparison should distinguish between direct and indirect evidence.

A direct comparative trial evaluates two products within the same study protocol. An indirect comparison draws information from separate studies, which may differ in important methodological details.

Evidence Question

Information Required

What product was investigated?

Verified brand and nonproprietary name

What dose was used?

Product-specific potency units

What condition was treated?

Indication and treatment area

Who participated?

Study population and eligibility criteria

How was efficacy assessed?

Primary endpoint and assessment method

How long was follow-up?

Study duration and visit schedule

What statistical conclusion was reached?

Superiority, non-inferiority or equivalence

What safety data were collected?

Adverse-event definitions and results

This framework helps prevent differences between study designs from being mistaken for differences between products.

10. Frequently Asked Questions

Are Dysport and BOTOX the same product?

No. Dysport contains abobotulinumtoxinA, while BOTOX contains onabotulinumtoxinA. They are distinct botulinum toxin type A products.

Can Dysport units be converted directly into BOTOX units?

Potency units are product-specific. A numerical dose ratio used in a clinical study should not be treated as a universal conversion formula.

Have Dysport and BOTOX been compared directly?

Yes. Published randomized clinical studies have evaluated abobotulinumtoxinA and onabotulinumtoxinA in defined indications, including glabellar lines. ［3］

Does non-inferiority mean that one product is superior?

No. Non-inferiority and superiority are different statistical objectives.

Which product has a faster onset?

Comparative onset findings must be interpreted according to the specific study, dose, indication and definition of onset. A result from one protocol should not be generalized to all clinical uses.

Which product lasts longer?

Duration comparisons require appropriately defined endpoints and follow-up data. Findings should remain tied to the studied treatment regimen.

Has Neuronox been compared directly with BOTOX?

Yes. A randomized Phase III study compared Neuronox with onabotulinumtoxinA in glabellar lines, and additional randomized studies have investigated selected therapeutic indications. ［5–8］

11. Conclusion

Dysport and BOTOX are distinct botulinum toxin type A products containing abobotulinumtoxinA and onabotulinumtoxinA, respectively.

Their potency units are product-specific, and numerical dose ratios investigated in clinical studies should not be treated as universal conversion formulas.

Published comparative research provides information about efficacy, onset and duration under defined protocols. These findings must be interpreted according to the investigated dose, population, indication, endpoint and follow-up period.

Neuronox also has a separate randomized clinical evidence program, including direct comparison with onabotulinumtoxinA in glabellar lines and studies in selected therapeutic indications.

An evidence-based comparison of botulinum toxin products should therefore distinguish product identity, formulation, potency units, approved indications and study-specific clinical outcomes.

References

［1］ Dysport (abobotulinumtoxinA). Official prescribing information. Ipsen. Current locally applicable version to be verified before publication.

［2］ BOTOX Cosmetic (onabotulinumtoxinA). Full Prescribing Information. AbbVie/Allergan Aesthetics. Current locally applicable version to be verified before publication.

［3］ Phase III randomized clinical study of abobotulinumtoxinA with an onabotulinumtoxinA active comparator in Chinese patients with glabellar lines. Full bibliographic details and study-specific outcomes to be verified against the original publication before publication.

［4］ Randomized comparative studies of onset and duration among incobotulinumtoxinA, onabotulinumtoxinA and abobotulinumtoxinA. Full bibliographic details and protocol-specific outcomes to be verified against the original publications before publication.

［5］ Lee WS, et al. Efficacy and safety of a new botulinum toxin type A for glabellar lines: randomized, double-blind, active-controlled, multicenter phase III study. Dermatologic Surgery. 2013;39:171–178. doi:10.1111/dsu.12072.

［6］ Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean Journal of Ophthalmology. 2009;23:137–141. doi:10.3341/kjo.2009.23.3.137.

［7］ Kim K, Shin HI, Kwon BS, et al. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Developmental Medicine & Child Neurology. 2011;53:239–244. doi:10.1111/j.1469-8749.2010.03830.x.

［8］ Nam HS, et al. Efficacy and safety of Neuronox versus BOTOX for post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS ONE. 2015;10:e0128633. doi:10.1371/journal.pone.0128633.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.